GlassScriptPhysician profile
Veronica L Leon
NPI 1588226914
$3,170.42
in general payments reported to CMS, 2019-2025
33 companies · $2,293 in 2025
The $2,293 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $88.68 · 2024: $789 · 2025: $2,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,775 · Long Term Medical Supply Or Device Loan: $897 · Education: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,774.99 |
| Long Term Medical Supply Or Device Loan | $897.30 |
| Education | $409.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,172.66 | 2024-2025 | |
| Lilly USA, LLC | $393.03 | 2024-2025 | Jaypirca, Retevmo, Verzenio |
| Janssen Biotech, INC. | $216.50 | 2024-2025 | Rybrevant, Tecvayli, Talvey |
| Amgen INC. | $198.54 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $128.49 | 2024-2025 | Keytruda, Welireg |
| Incyte Corporation | $104.34 | 2024-2025 | Pemazyre, Monjuvi, Jakafi |
| Daiichi Sankyo INC. | $101.90 | 2024-2025 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $80.59 | 2024-2025 | Imfinzi, Calquence |
| Genentech USA, INC. | $76.29 | 2024-2025 | Venclexta, Itovebi, Perjeta |
| Springworks Therapeutics, INC. | $75.75 | 2025 | Ogsiveo |
| Eisai INC. | $67.44 | 2024-2025 | |
| Novocure INC. | $62.79 | 2024-2025 | Optune Lua (Novottf-200t) |
| Abbvie INC. | $45.37 | 2024-2025 | |
| Beigene USA, INC. | $40.89 | 2024-2025 | Tevimbra, Brukinsa |
| Pfizer INC. | $38.24 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $31.01 | 2025 | Onivyde |
| Alnylam Pharmaceuticals INC. | $26.18 | 2024 | Givlaari |
| Alexion Pharmaceuticals, INC. | $22.66 | 2025 | Ultomiris |
| Aveo Pharmaceuticals, INC. | $22.22 | 2025 | |
| Lundbeck LLC | $21.99 | 2024 | Vyepti |
| Octapharma USA, INC. | $21.96 | 2024 | Octagam Immune Globulin (Human) |
| Tersera Therapeutics LLC | $21.91 | 2024 | Zoladex |
| Takeda Pharmaceuticals U.S.A., INC. | $21.87 | 2025 | Ninlaro |
| Taiho Oncology, INC. | $21.09 | 2025 | |
| Averitas Pharma INC. | $19.73 | 2024 | Qutenza |
| Celgene Corporation | $19.21 | 2025 | Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $18.82 | 2024 | |
| Puma Biotechnology, INC. | $18.76 | 2025 | |
| Agios Pharmaceuticals, INC. | $16.50 | 2024 | Pyrukynd |
| Emd Serono, INC. | $16.39 | 2025 | |
| Glaxosmithkline, LLC. | $16.33 | 2024 | Jemperli |
| Exelixis INC. | $16.17 | 2025 | Cabometyx |
| Astellas Pharma US INC | $14.80 | 2025 | Vyloy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Leon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.